WHY KINETISOL TECHNOLOGY IS DISRUPTING SPRAY DRYING

Dave Miller, AustinPx CSO's (Chief Scientific Officer) talk begins by showcasing two case studies of commercial spray dried dispersions— replicated with KinetiSol and eliminating toxic solvents, manufacturing complexity, and improving drug product properties.

Springboarding from these case studies, Dave then focuses on the facility, utilities, and downstream processing requirements for SDDs and contrasts those with the same for KinetiSol.

The second half of dives into the biopharmaceutical performance benefits achievable with KinetiSol when compared to spray drying. This is demonstrated by a series of case studies and explained with rigorous analytical data.

At the end of the lecture, the audience will have a better understanding that KinetiSol is a commercially-ready process not only capable of reproducing SDDs with far less manufacturing complexity and environmental impact, but also with the capability to out design and outperform spray drying.

LEARN MORE ABOUT:

• How to improve the bioavailability of poorly soluble drugs
• How to save time with KinetiSol's fusion-based, solvent free process
• The next generation of amorphous dispersion technology